- Associate Professor
Daniel Craven, MD, is a specialist in pediatric pulmonary (lung) diseases in the Division of Pediatric Pulmonology, Allergy, Immunology and Sleep Medicine, medical director of respiratory therapy, clinical director of the Technology Dependent Center, and co-director of the Children’s Asthma Center at University Hospitals Rainbow Babies & Children’s Hospital. He sees patients at UH Landerbrook, UH Medina and UH Westlake health centers.
Dr. Craven has been voted to Cleveland Magazine’s Top Doctors multiple times and was recently selected for “Best Doctors in America.”
Dr. Craven is board certified in pediatric pulmonology. His special interests include pediatric asthma, bronchiectasis, mechanical ventilation in children, vocal cord dysfunction, respiratory complications of sickle cell anemia, respiratory complications of Down syndrome, diffuse parenchymal lung disease, and rare lung disease. He was appointed to the UH Rainbow Babies & Children’s Hospital medical staff in 1996.
Dr. Craven is a graduate of Duke University, Durham, N.C., graduating cum laude with a bachelor’s degree in psychology. He earned his medical degree from Case Western Reserve University School of Medicine and served his residency and chief residency in pediatrics and a fellowship in pediatric pulmonology at UH Rainbow Babies & Children’s Hospital.
Dr. Craven has authored or coauthored scientific papers in pediatric and pulmonary medicine journals and has been an invited presenter at The American Thoracic Society International Conference as well as at local medical symposia and Grand Rounds, speaking on pediatric asthma and a wide spectrum of pediatric pulmonary disorders.
- Diffuse and rare childhood lung disease (chILD)
- Down syndrome pulmonary complications
- Sickle cell pulmonary complications
- Quality improvement
- Pediatric asthma
- Allergic Respiratory Disorders
- Bronchopulmonary Dysplasia
- Childhood Interstitial Lung Disease
- Children Dependent on Mechanical Ventilation
- Chronic Cough
- Chronic Lung Disease
- Cystic Fibrosis
- Exercise Associated Dyspnea
- Pulmonary Complications of Trisomy 21
- Rare Lung Disease
- Recurrent Pneumonia
- Sickle Cell Respiratory Disorders
- Swallowing Disorders
- Vocal Cord Dysfunction
- Pediatric Pulmonology - American Board of Pediatrics
Fellowship | Pediatric Pulmonology
Pediatric Pulmonology - University Hospitals Of Cleveland (1997 - 2000)
Residency | Pediatrics/Chief Resident
Pediatrics/Chief Resident - University Hospitals Of Cleveland (1996 - 1997)
Residency | Pediatrics
Pediatrics - University Hospitals Of Cleveland (1994 - 1996)
Internship | Pediatrics
Pediatrics - University Hospitals Of Cleveland (1993 - 1994)
Case Western Reserve University School Of Medicine (1993)
Duke University (1987)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Daniel Craven did not disclose any Outside Relationships with Industry.